<DOC>
	<DOCNO>NCT01202877</DOCNO>
	<brief_summary>The goal clinical research study learn combination PKC412 ( also call Midostaurin ) 5-azacytidine help control refractory relapse acute leukemia MDS . The safety best dose combination drug also study .</brief_summary>
	<brief_title>PKC412 5-Azacytidine</brief_title>
	<detailed_description>The Study Drugs : PKC412 design block certain receptor ( FLT3-Kinase ) cancer cell responsible cancer growth . This may cause cancer cell die . 5-azacytidine design cause change certain gene think participate cause leukemia . These change think silence gene contribute long sustain growth leukemia MDS . Study Groups : If find eligible take part study , assign part study base join . - If one first 6 participant , receive pre-planned dose study drug . If 2 participant experience severe side effect , rest group receive low dose . - If one first 6 participant , few 2 patient severe side effect first group , receive drug higher dose first 6 participant . Study Drug Administration : You receive 5-azacytidine vein 30 minute needle skin Days 1-7 28-day study cycle . Your doctor decide get drug vein skin . You require return MD Anderson first 7 day every cycle receive 5-azacytidine . On Days 8-21 cycle 1 , take PKC412 capsule mouth 2 time day . Starting Cycle 2 , take PKC412 capsule mouth every day . The research staff tell take study drug also give instruction . If severe side effect study drug , study doctor may decide stop drug dose side effect improve . Study Visits : At every visit , ask side effect experienced list drug may take . - At start Cycles 1-2 ( +/- 4 day ) every 2-3 cycle , complete physical exam . - Every week Cycles 1-3 ( +/- 4 day ) every 2-4 week , blood ( 1 tablespoon ) drawn routine test test kidney liver function . - On Day 28 Cycle 1 ( +/- 4 day ) every 1-3 cycle , bone marrow aspirate check status disease . - On Day 8 ( +/- 1 day ) cycle first cycle initiation Midostaurin , start Midostaurin Cycle 2 , Day 1 every 2-3 Cycles , ECG . - On Days 8 , 15 , 21 Cycle 1 Day 1 Cycle 2 , blood ( 1 teaspoon ) drawn PK test take study drug . If stay study longer 6 month , doctor decide test procedure perform . At least every 6-12 month bone marrow aspirate . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad intolerable side effect occur . This investigational study . PKC412 FDA approve commercially available . It currently use research purpose . 5-azacytidine FDA approve commercially available treatment patient MDS . The combination drug treat refractory relapse acute leukemia MDS investigational . Up 54 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>1 . Patients MDS , chronic myelomonocytic leukemia ( CMML ) , AML biphenotypic bilineage leukemia fail prior therapy . Patients MDS CMML fail prior therapy hypomethylating agent and/or lenalidomide . Patients AML fail prior induction therapy relapse prior therapy , previously untreated unable unwilling receive conventional chemotherapy ( e.g. , patient age &gt; /=65 year ) . Patients MDS CMML receive therapy hypomethylating agent progress AML eligible time diagnosis AML regardless prior therapy AML . The WHO classification use AML . Patients MDS , CMML AML receive prior therapy eligible candidate receive refuse standard therapy . 2 . Patients must evidence FLT3 activate mutation . 3 . Age &gt; /= 18 year 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; /= 2 5 . Adequate liver ( bilirubin &lt; /= 2x ULN , ALT &lt; /= 2.5x ULN ) renal ( creatinine &lt; /= 2x ULN ) function 6 . Patients must provide write informed consent . 7 . Patients must chemotherapy 2 week prior enter study , unless evidence rapidly progressive disease , must recover toxic effect therapy least grade 1 . Use hydroxyurea patient rapidly proliferative disease allow start study therapy first four week therapy . 8 . Women childbearing potential must practice contraception . Women consider childbearing potential include follow : menses least 5 year menses within 5 year amenorrheic least 2 month luteinizing hormone ( LH ) follicular stimulate hormone ( FSH ) value within normal range ( accord definition postmenopausal laboratory use ) bilateral oophorectomy radiation castration amenorrheic least 3 month . Females childbearing potential : Recommendation 2 effective contraceptive method study . Adequate form contraception double barrier method ( condom spermicidal jelly foam diaphragm spermicidal jelly foam ) , oral , depo provera , injectable contraceptive , intrauterine device , tubal ligation . 9 . **continued : Male patient female partner childbearing potential : Recommendation male partner use least 2 effective contraceptive method , describe , study . 10 . Sexually active male use condom intercourse take drug 3 month stop midostaurin medication . They father child period . A condom require use also vasectomize men order prevent delivery drug via seminal fluid . 11 . Negative urine serum pregnancy test within 2 week . 1 . Patients know allergy hypersensitivity PKC412 , mannitol 5azacytidine , component . 2 . Patients receive treatment midostaurin prior study entry . 3 . Patients know impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption PKC412 . 4 . Patients demonstrate primary resistance FLT3 inhibitor relapse therapy FLT3 inhibitor . 5 . Patients know disease ( except carcinoma insitu ) concurrent severe and/or uncontrolled medical condition ( e.g . uncontrolled diabetes fast glucose &gt; 200 mg/dl despite optimal management , cardiovascular disease include congestive heart failure ( NYHA Class III IV ) , myocardial infarction within 6 month poorly control hypertension systolic &gt; 160 mmHg diastolic &gt; 100 mmHg , chronic renal disease , active uncontrolled systemic infection ) could compromise participation study . 6 . Patients know confirmed diagnosis HIV infection active viral hepatitis . HIV patient specific antiretroviral therapy eligible participation . 7 . Patients major surgical procedure within 14 day Day 1 . 8 . Patients unwilling unable comply protocol . 9 . Patients know advanced malignant disease central nervous system . 10 . Impaired cardiac function include follow : Screening ECG correct QT interval ( QTc ) &gt; 470 msec ; Patients congenital long QT syndrome ; History presence sustain ventricular tachycardia ; Any history ventricular fibrillation torsades de pointes ; Bradycardia define HR &lt; 50 bpm ; Right bundle branch block + leave anterior hemiblock ( bifascicular block ) ; Patients myocardial infarction unstable angina &lt; 6 month prior start study drug ; congestive heart failure ( CHF ) NY Heart Association class III IV ; Patients ejection fraction &lt; 50 % assess multigated radionuclide angiography ( MUGA ) ECHO scan within 14 day Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Refractory acute leukemia</keyword>
	<keyword>Relapsed acute leukemia</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>5-Azacytidine</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-aza</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
	<keyword>PKC412</keyword>
</DOC>